Addex Pharmaceuticals and the Pursuit of the True Innovation

In this conversation with Dr. Vincent Mutel, co-founder and CEO of Addex Pharmaceuticals, Fintan Walton reveals how the Addex mission—to achieve true innovation—has contributed to the tremendous success of this young biotech company. Addex discovers and develops allosteric modulators, with a focus on those that target G-Protein Coupled Receptors (GPCRs), a class of receptors that have proven therapeutic utility in many diseases. Dr. Mutel believes that this kind of innovative approach is the mission of biotech and that this innovation is the “currency” of biotech and will provide the necessary funding for worthwhile projects. Addex has seen its own work validated through high-profile deals with Johnson & Johnson and Merck & Co. and a 2007 IPO offering that was one of the largest in Europe for several years.

Source : PharmaTelevision